Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflam… Read more
Nkarta Inc (NKTX) - Net Assets
Latest net assets as of September 2025: $337.90 Million USD
Based on the latest financial reports, Nkarta Inc (NKTX) has net assets worth $337.90 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($427.24 Million) and total liabilities ($89.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $337.90 Million |
| % of Total Assets | 79.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | 27.01% |
| 10-Year Change | N/A |
| Growth Volatility | 36.55 |
Nkarta Inc - Net Assets Trend (2018–2024)
This chart illustrates how Nkarta Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nkarta Inc (2018–2024)
The table below shows the annual net assets of Nkarta Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $407.98 Million | +49.29% |
| 2023-12-31 | $273.29 Million | -26.58% |
| 2022-12-31 | $372.21 Million | +48.31% |
| 2021-12-31 | $250.97 Million | -21.87% |
| 2020-12-31 | $321.22 Million | +1360.55% |
| 2019-12-31 | $-25.48 Million | -372.25% |
| 2018-12-31 | $-5.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nkarta Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53864009300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $674.00K | 0.17% |
| Other Components | $951.52 Million | 233.23% |
| Total Equity | $407.98 Million | 100.00% |
Nkarta Inc Competitors by Market Cap
The table below lists competitors of Nkarta Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu United Water Technology Co. Ltd. Cl A
SHG:603291
|
$130.64 Million |
|
Sligro Food Group N.V.
PINK:SIGRF
|
$130.70 Million |
|
Adira Dinamika Multi Finance
JK:ADMF
|
$130.76 Million |
|
Shanghai Longyun Advg & Media
SHG:603729
|
$130.76 Million |
|
Belpointe REIT Inc
OTCQX:BELP
|
$130.61 Million |
|
Zhejiang Jindao Technology Co. Ltd.
SHE:301279
|
$130.56 Million |
|
Axtel S.A.B. de C.V
OTCGREY:AXTLF
|
$130.56 Million |
|
Geospace Technologies Corporation
NASDAQ:GEOS
|
$130.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nkarta Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 273,285,000 to 407,976,000, a change of 134,691,000 (49.3%).
- Net loss of 108,790,000 reduced equity.
- New share issuances of 225,073,000 increased equity.
- Other comprehensive income increased equity by 666,000.
- Other factors increased equity by 17,742,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-108.79 Million | -26.67% |
| Share Issuances | $225.07 Million | +55.17% |
| Other Comprehensive Income | $666.00K | +0.16% |
| Other Changes | $17.74 Million | +4.35% |
| Total Change | $- | 49.29% |
Book Value vs Market Value Analysis
This analysis compares Nkarta Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.39x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.11 | $2.32 | x |
| 2019-12-31 | $-2.84 | $2.32 | x |
| 2020-12-31 | $10.10 | $2.32 | x |
| 2021-12-31 | $7.64 | $2.32 | x |
| 2022-12-31 | $8.53 | $2.32 | x |
| 2023-12-31 | $5.58 | $2.32 | x |
| 2024-12-31 | $6.01 | $2.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nkarta Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-26.67%) is below the historical average (-23.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -4.19% | 0.68x | 0.00x | $265.10K |
| 2019 | 0.00% | -18265.66% | 0.00x | 0.00x | $-18.53 Million |
| 2020 | -28.44% | -23730129.87% | 0.00x | 1.05x | $-123.48 Million |
| 2021 | -33.45% | 0.00% | 0.00x | 1.09x | $-109.05 Million |
| 2022 | -32.09% | 0.00% | 0.00x | 1.27x | $-156.65 Million |
| 2023 | -43.00% | 0.00% | 0.00x | 1.39x | $-144.83 Million |
| 2024 | -26.67% | 0.00% | 0.00x | 1.23x | $-149.59 Million |
Industry Comparison
This section compares Nkarta Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nkarta Inc (NKTX) | $337.90 Million | 0.00% | 0.26x | $130.63 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |